A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress Syndrome

A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Continuous Intravenous Infusion of STC314 Injection in Chinese Patients With Acute Respiratory Distress Syndrome

This study is a Randomized, Double-blinded, Placebo-controlled Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STC314 Injection Administered as Continuous Intravenous Infusion in Chinese Patients with ARDS (Acute Respiratory Distress Syndrome).

Study Overview

• Status: Recruiting
• Conditions: Acute Respiratory Distress Syndrome
• Intervention / Treatment: Drug: STC314 injection or Placebo(rate=58.3 mg/hr); Drug: STC314 injection or Placebo(rate=87.5 mg/hr)

• Study Type: Interventional
• Enrollment (Anticipated): 16
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: James Pang, PhD; Phone Number: +61 466555916; Email: jpang@grandpharma.cn

Study Locations

• China
  • Hebei
    • Shijiazhuang, Hebei, China
      • Not yet recruiting
      • The Fourth Hospital of Hebei Medical University
      • Contact: Zhenjie Hu, MD; Email: syicu@vip.sina.com
  • Hubei
    • Wuhan, Hubei, China
      • Not yet recruiting
      • Wuhan Jinyintan Hospital
      • Contact: Wenjuan Wu, MD; Email: 1346801465@qq.com
    • Wuhan, Hubei, China
      • Recruiting
      • Wuhan Union Hospital
      • Contact: Shiying Yuan, MD; Email: yuan_shiying@163.com
  • Hunan
    • Changsha, Hunan, China
      • Not yet recruiting
      • Xiangya Hospital Central South University
      • Contact: Pinhua Pan, MD; Email: Pinhuapan668@126.com
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Recruiting
      • Zhongda Hospital Southeast University
      • Contact: Haibo Qiu, MD; Email: haiboq2000@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. 18 ≤ age ≤ 70 years, male or female;
2. Voluntarily participate in the study and sign the informed consent form;
3. Diagnosis of ARDS for no more than 48 hours (starting at the time of diagnosis recorded in the medical record)；

4. The following 2012 Berlin definition criteria for mild to moderate ARDS were met:

   1. From known clinical impairment and new or worsening of respiratory symptoms to fulfillment of diagnostic criteria is less than 7 days(inclusive).
   2. Chest imaging suggests bilateral infiltrates. The effusion, lobar/atelectasis, or nodules cannot completely explain the phenomenon.
   3. Respiratory failure cannot be completely explained by heart failure or fluid overload;
   4. When PEEP or CPAP ≥5 cm H2O, 100 mmHg≤PaO2/FiO2≤300 mmHg;
5. Male subjects agree to use an effective contraceptive method from the start of the study until 7 days after the end of treatment; Female subjects of childbearing age agree to use an effective contraceptive method from the start of the study until 3 months after the end of treatment.

Exclusion Criteria:

1. Positive serum pregnancy test before dosing for women of childbearing potential, pregnant women, or lactating women;
2. Terminal phase of chronic disease with an expected survival of no more than 6 months;

3. Combined with one of the following chronic organ damage or immunosuppressive diseases:

   1. Heart: New York Heart Association functional class IV;
   2. Lung: severe lung disease, including pulmonary hypertension, oxygen therapy or ventilator dependence for more than one month cumulatively within the first six months of screening, end-stage lung disease, or severe exercise limitation caused by chest wall malformations;
   3. Kidney: ongoing long-term dialysis treatment;
   4. Liver: biopsy confirmed cirrhosis and portal hypertension, or previous upper gastrointestinal bleeding caused by portal hypertension; Liver failure, hepatic encephalopathy, or hepatic coma;
   5. Immunosuppression: with lymphoma, leukemia or acquired immunodeficiency; Received anti-tumor chemotherapy in the last 3 months, or ongoing immunosuppressive therapy due to organ transplantation, immune diseases, etc.; Has undergone allogeneic bone marrow transplantation or hematopoietic stem cell transplantation; Steroid hormone therapy in the last 3 months (equivalent to > 0.5 mg/kg/day prednisone continued 1 month);

4. History of one of the following within 4 weeks prior to screening:

   1. Acute pulmonary embolism;
   2. Cardiac arrest;
   3. Acute myocardial infarction;
5. eGFR < 60 mL/min/BSA (calculated using CG formula);
6. ALT > 5 x ULN, or total bilirubin > 2 x ULN;
7. Severe anemia (hemoglobin < 7.0 g/dL);
8. Absolute neutrophil count < 1500/μL;
9. Platelet count < 50,000/μL;
10. aPTT > 1.5 × ULN;
11. Active bleeding that cannot be effectively controlled;
12. The subject required therapeutic doses of heparin or was taking anticoagulants;
13. ARDS caused by direct lung injury due to physical or chemical causes;
14. Severe or greater burns: the overall surface area of burns exceeds 30% or the III degree burn area exceeds 10%; or the total area is less than 30%, but the general condition is severe or has shock, combined injury, respiratory tract burn;
15. Allergic to the active ingredients or excipients of the study drug;
16. Subjects have participated in other clinical studies (other than those who have not received intervention) or are participating in other experimental treatments within 1 month prior to screening;
17. In the opinion of the investigator, the subject could not benefit from the study or was not suitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; Drug: STC314/Placebo injection Continuous infusion at rate 58.3mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)	Drug: STC314 injection or Placebo(rate=58.3 mg/hr); To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
Experimental: Cohort 2; Drug: STC314/Placebo injection Continuous infusion at rate 87.5mg/hr up to 3 days (72 hours) N=8(Randomization-STC314/Placebo injection=3:1)	Drug: STC314 injection or Placebo(rate=87.5 mg/hr); To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the safety of STC314 injection in patients with ARDS.	The incidence of adverse event (AE) and serious adverse event (SAE);	Within 28 days after the start of treatment
To evaluate the safety of STC314 injection in patients with ARDS.	Rates of Treatment Discontinuation Due to Adverse Events;	Within 28 days after the start of treatment
To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	maximum concentration (Cmax)	Through 0 to144 hours after the start of treatment
To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	area under the plasma concentration-time curve (AUC0-t, AUC0-inf)	Through 0 to144 hours after the start of treatment
To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	time to peak (Tmax)	Through 0 to144 hours after the start of treatment
To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	elimination half Decay (t1/2)	Through 0 to144 hours after the start of treatment
To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	elimination rate constant(Kel)	Through 0 to144 hours after the start of treatment
To evaluate the pharmacokinetic of STC314 injection in patients with ARDS.	clearance (CL)	Through 0 to144 hours after the start of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the efficacy of STC314 injection in patients with ARDS.	Changes of the value of blood lactate from baseline after dosing	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of Oxygenation Index (PaO2/FiO2) from baseline after dosing	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of Murray Lung Injury Score from baseline.(range 0-4, higher score means more severe lung injury)	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of the value of serum creatinine from baseline after dosing	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of the value of bilirubin from baseline after dosing	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of the value of Alanine Transaminase(ALT) from baseline after dosing	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Change of Sequential Organ Failure Assessment score from baseline after dosing.(range 0-4, higher score means a worse prognosis)	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	all-cause mortality within 28 days	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Ventilator-free survival time within 28 days	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	Hospitalization time within 28 days	Within 28 days after the start of treatment
To evaluate the efficacy of STC314 injection in patients with ARDS.	length of ICU stay within 28 days	Within 28 days after the start of treatment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.	Change of the level of Histone in plasma after dosing	Through 0 to144 hours after the start of treatment
As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.	Change of the level of Neutrophil extracellular traps(NETs)-related variables in plasma after dosing [myelinated Oxidase (MPO), citrullinated histone H3 (CitH3), circular free DNA (cfDNA)]	Through 0 to144 hours after the start of treatment
As an exploratory objective, the change in biomarkers from baseline following STC314 injection treatment in subjects with Acute Respiratory Distress Syndrome will be evaluated.	Change of the level of inflammatory factor interleukin-6 (IL-6) after dosing	Through 0 to144 hours after the start of treatment

Collaborators and Investigators

• Sponsor: Grand Medical Pty Ltd.
• Collaborators: Grand Pharmaceutical (China) Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): July 28, 2021
• Primary Completion (Anticipated): December 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: July 27, 2021
• First Submitted That Met QC Criteria: August 3, 2021
• First Posted (Actual): August 11, 2021

Study Record Updates

• Last Update Posted (Actual): December 27, 2021
• Last Update Submitted That Met QC Criteria: December 23, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Disease; Infant, Newborn, Diseases; Lung Injury; Infant, Premature, Diseases; Syndrome; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury
• Other Study ID Numbers: GPHIP-0103

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No